Search

Search Constraints

You searched for: Author/Creator Arranz, R.

Search Results

1. AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST‐LINE THERAPY IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY. (12th June 2019)

2. AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGATE THE NEGATIVE PROGNOSTIC EFFECT OF EARLY RELAPSE AFTER CHEMO OR INMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA. (June 2017)

3. BENDAMUSTINE AS PART OF CONDITIONING REGIMEN FOR AUTOLOGOUS STEM‐CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE LYMPHOMAS: FINAL ANALYSIS OF A PHASE 2 STUDY FROM GELTAMO. (June 2017)

4. Can we improve the classification of ampullary adenocarcinoma? the value of histomolecular classification and clinicopatothological features on prognosis. (2021)

6. Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients. (March 2019)

7. LONG‐TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT‐2008‐01). (June 2017)

8. PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX‐ AND AGE‐MATCHED SPANISH GENERAL POPULATION. (June 2017)